SODIUM ACETATE Drug Patent Profile
✉ Email this page to a colleague
When do Sodium Acetate patents expire, and what generic alternatives are available?
Sodium Acetate is a drug marketed by Fresenius Kabi Usa, Hikma, Hospira, and Milla Pharms. and is included in four NDAs.
The generic ingredient in SODIUM ACETATE is sodium acetate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sodium acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Acetate
A generic version of SODIUM ACETATE was approved as sodium acetate by HOSPIRA on May 4th, 1983.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SODIUM ACETATE?
- What are the global sales for SODIUM ACETATE?
- What is Average Wholesale Price for SODIUM ACETATE?
Summary for SODIUM ACETATE
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 230 |
| Patent Applications: | 2,172 |
| Drug Prices: | Drug price information for SODIUM ACETATE |
| What excipients (inactive ingredients) are in SODIUM ACETATE? | SODIUM ACETATE excipients list |
| DailyMed Link: | SODIUM ACETATE at DailyMed |
Pharmacology for SODIUM ACETATE
| Drug Class | Osmotic Laxative |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM ACETATE
US Patents and Regulatory Information for SODIUM ACETATE
SODIUM ACETATE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting SODIUM ACETATE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 206687-001 | Oct 30, 2017 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 018893-003 | Sep 2, 2014 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 216920-003 | Mar 15, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Milla Pharms | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 214805-004 | Jan 22, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 216920-001 | Mar 15, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
